This study aims to explore the changes in metabolic-related indicators in patients with hyperuricemia under the intervention of barley green, reveal the clinical effect of barley green in regulating uric acid metabolism, and preliminarily clarify the mechanism of barley green influencing uric acid metabolism through in vitro experiments related to xanthine oxidase. This study plans to recruit patients with hyperuricemia who visit the clinical nutrition department and rheumatology and immunology department of Peking University People's Hospital, randomly dividing them into an intervention group and a control group. The intervention group will take barley green plus a balanced diet plan, while the control group will only be given a balanced diet plan. General clinical data will be collected, and nutritional measurements will be conducted. Venous blood will be drawn for the determination of uric acid metabolism-related indicators, xanthine oxidase activity, and inflammatory factor levels. The differences in uric acid and related metabolic indicators, as well as xanthine oxidase activity, between the two groups will be observed and compared to provide a scientific basis for the clinical application of barley green in non-pharmacological intervention and medical nutrition therapy for hyperuricemia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
Peking University People's Hospital
Beijing, Xicheng District, China
uric acid levels in umol/L
Uric acid levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
Xanthine oxidase activity in ng/mL
Xanthine oxidase activity was measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
erythrocyte sedimentation rate in mm/h
Erythrocyte sedimentation rates were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
antinuclear antibody in semi-quantitative
Antinuclear antibodies were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
blood glucose in mmol/L
Blood glucoses were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
total cholesterol in mmol/L
Total cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
triglycerides in mmol/L
Triglycerides were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
high-density lipoprotein cholesterol in mmol/L
High-density lipoprotein cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
low-density lipoprotein cholesterol in mmol/L
Low-density lipoprotein cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
C-reactive protein in mg/L
C-reactive proteins were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
white blood cell count in 10^9/L
White blood cell counts were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
leptin level in pg/mL
Leptin levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
adiponectin level in ug/mL
Adiponectin levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
IL-1β in pg/mL
IL-1β levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
IL-2 in pg/mL
IL-2 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
IL-4 in pg/mL
IL-4 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
IL-6 in pg/mL
IL-6 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
IL-10 in pg/mL
IL-10 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
IFN-γ in pg/mL
IFN-γ levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
TNF-α in pg/mL
TNF-α levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
height in centimeters
Height in centimeters were measured by Manual Height Ruler at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
weight in kilograms
Weight in kilograms were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
BMI in kg/m^2
Weight and height will be combined to report BMI in kg/m\^2 at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
body fat rate in %
Body fat rates were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
muscle mass in kilograms
Muscle masses were measured by were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
basal metabolic rate in kcal
Basal metabolic rates were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
skeletal muscle mass in kilograms
Skeletal muscle masses were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
blood pressure in mmHg
Blood pressures were measured by electronic blood pressure monitor at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
waist circumference in millimeters
Waist circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
hip circumference in millimeters
Hip circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
upper arm circumference in millimeters
Upper arm circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
left hand grip strength in pound-force
Left hand grip strengths were measured by grip dynamometer at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
right hand grip strength in pound-force
Right hand grip strengths were measured by grip dynamometer at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
triceps skinfold thickness in millimeters
Triceps skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
subscapular horn skinfold thickness in millimeters
Subscapular horn skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
abdominal skinfold thickness in millimeters
Abdominal skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
food intake dose in grams
Data of food intake doses were taken by food frequency questionnaire and 3-day food diary at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Time frame: From enrollment to the end of treatment at 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.